Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Biology » Biology - General » Drug-Resistant Tuberculosis: Causes, Diagnosis and Treatments Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Carbohydrate Metabolism: Theory and Practical Approach
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Tuberculosis — The Development of New MDR-TB Drugs
Tell A Friend
Tell someone you know about this product.
Tuberculosis — The Development of New MDR-TB Drugs $100.00
Authors:  Jarmila Vinšová and Martin Krátký
The aim of this review is to outline the recent advances in the development of new
multidrug-resistant tuberculosis (MDR-TB) drugs. The emergence of resistance to
antituberculosis drugs, particularly of MDR-TB and more recently XDR-TB, has become
a major public health problem. The current treatment regimen has several disadvantages,
i.e. long treatment period (DOTS takes minimum 6 months) during which tubercle bacilli
mutant becomes resistant to one or more drugs; side effects of the used drugs; coinfection
of HIV/AIDS. The emergence of MDR-TB has made many currently available
anti-TB drugs ineffective. Sleeping latent forms of mutant bacilli resistant to common
anti-TB drugs create the risk of epidemic for the new generation. Therefore, there is an
urgent need to identify new drug targets and to find novel chemical structures active
especially against MDR-TB.
In general, drug resistance mechanisms in Mycobacterium tuberculosis are caused
by mutations in chromosomal genes. It includes target modifications, barrier mechanism,
inactivation or activation of enzymes, mutation in the genes such as inhA, rpoB, rpsL,
rrs, emrB and gyrA, responsible for INH, RIF, STM, EMB and quinolone resistances.
Some novel targets as an essential cell division protein (FtsZ), ATP-synthase target,
isocitrate lyase, targeting P450 enzymes, etc., are presented. The research of novel MDR
potential drugs follows six main strategies: a) structure modification of known
compounds (INH, RIF, PZA, ETH, EMB, quinolones); b) new leads with novel
mechanism of action (linezolid, TMC207, PA-824, OPC-67683, BM212, SQ109,
FAS20013, LL-3858); c) novel drug targets, i.e. cell wall biosynthesis (mycolic acid
synthesis, protein synthesis, arabinogalactan and peptidoglycan biosynthesis inhibitors)
or other novel targets like enzymes; d) investigation of “non-antituberculous” drugs; e) testing of newly prepared synthetic compounds without known mechanism of action; f)
screening of natural products, determination and isolation of active compounds. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Global Political Economy after the Crisis: Theoretical Perspectives and Country Experiences
02.Palliative Care: Perspectives, Practices and Impact on Quality of Life. A Global View, Volume 1
03.Trace Metals: Evolution, Environmental and Ecological Significance
04.Informal Learning: Perspectives, Challenges and Opportunities
05.Dissolved Organic Matter (DOM): Properties, Applications and Behavior
06.Green Polymeric Materials: Advances and Sustainable Development
07.Readings in the 20th Century Genocide of the Syriac Orthodox Church of Antioch (Sayfo)
08.Human Collaboration in Homeland Security (DVD Included)
09.Health and Freedom in the Balance: Exploring the Tensions among Public Health, Individual Liberty, and Governmental Authority
10.Innovations in Dialysis Vascular Access Surgery
11.Major Depressive Disorder: Risk Factors, Characteristics and Treatment Options
12.Inulin: Chemical Properties, Uses and Health Benefits

Nova Science Publishers
© Copyright 2004 - 2017

Tuberculosis — The Development of New MDR-TB Drugs